JERUSALEM, April 18 /CNW/ -- Oramed Pharmaceuticals, Inc. (OTC Bulletin
Board: ORMP)(FTSE: OJU) invites everybody to join Nadav Kidron on
www.Wallst.net to discuss the future of Oramed Pharmaceuticals Inc., and
update the investment community on the present status of the company. The
interview will take place at 3pm Eastern time on Thursday, April 19. It will
be broadcast live on their website and then archived into their records for
future reference. If you have any specific questions to be asked, please email
them to firstname.lastname@example.org and they will be forwarded on Thursday morning
to the interviewer.
To hear the interview in its entirety, please visit
http://www.wallst.net/ and click on "Interviews". The interview can be
accessed either by locating the Company's ticker symbol (ORMP) under the
appropriate exchange (OTCBB) on the left-hand column of the "Interviews"
section of the site, or by entering the Company's ticker symbol in the Search
CEO Nadav Kidron stated, "I look forward to hearing a public response to
our company's efforts and successes over the past year."
About Oramed Pharmaceuticals, Inc:
Oramed Pharmaceuticals Inc. is an Israeli company focused on the
development of oral delivery solutions based on proprietary technology.
Diabetes is one of the most rapidly growing diseases in the world and is one
that requires constant and often unpleasant monitoring and drug therapy
regimen. Oramed is currently developing an orally ingestible soft gel insulin
capsule for the treatment of diabetes. The Company is also pursuing the
development of oral delivery solutions for other drugs and vaccines.
For more information on Oramed Pharmaceuticals please visit our website
Legal Notice Regarding Forward Looking Statements
This news release contains statements, which may constitute "forward-
looking statements". Those statements include statements regarding the intent,
belief or current expectations of Oramed as well as the assumptions on which
such statements are based. Forward-looking statements in this release include:
that we are currently developing an orally soft gel insulin capsule for the
treatment of diabetes; and that we are also pursuing the development of oral
delivery solutions for other drugs and vaccines. Factors which may
significantly change or prevent our forward looking statements from fruition
include that we may be unsuccessful in developing any products; we may be
unable to raise funds and resources to pursue research and development; we may
be unable to successfully defend our patents from infringement by third
parties, there is a risk that our patents may be subsequently shown to be
invalid or infringe the patents of others; we may be unable to attract or
retain our key employees, consultants and advisors, our products may never
gain FDA or other regulatory body approval for human consumption and we may be
unable to successfully commercialize our future products. Readers should refer
to our most recent 10-KSB filed on Edgar and the 8-K announcing our
acquisition of the Oramed technology filed March 8, 2006.
For further information:
For further information: Vinisha Agnihotri of Oramed Pharmaceuticals,
Inc., +1-646-467-2252, email@example.com Web Site: